GLP-1 Telehealth Providers in California

Yes. California fully supports telehealth prescribing of GLP-1 medications. Most major telehealth platforms are available in California.

California requires informed consent for telehealth visits and has specific consumer protection laws. Providers must be licensed in California.

California has the widest provider availability of any state, with virtually all major telehealth GLP-1 platforms operating there.

Medi-Cal covers GLP-1 medications for weight management if you have a BMI of 30 or higher, or 27 or higher with a weight-related condition such as high blood pressure or sleep apnea. Prior authorization is required, and coverage depends on your specific Medi-Cal managed care plan. Contact your plan directly to confirm formulary inclusion.

The FDA removed semaglutide from its drug shortage list in early 2025, ending 503B outsourcing facility compounding. California-licensed 503A pharmacies may still compound semaglutide for individual patients under certain circumstances, but availability has narrowed. Ask your telehealth provider whether they can still source compounded semaglutide through a licensed 503A pharmacy.

No physician referral is needed. Telehealth providers can evaluate and prescribe directly. If you're paying through insurance, prior authorization is usually required. Cash-pay programs have no referral requirement and typically issue a prescription within 24–72 hours of your intake.

Most California-available telehealth programs operate asynchronously — you complete a health intake, lab review (sometimes waived), and get a prescription decision within 24–48 hours. Synchronous video consultations are also available and typically scheduled within 2–5 days. Medication shipment adds 3–7 days depending on the pharmacy.